Innova Vascular Reports Successful Early Commercial Use of Laguna Thrombectomy System

February 7, 2024—Innova Vascular, Inc. announced early successful commercial use of the Laguna thrombectomy system by physicians at UCLA Medical Center in Los Angeles, California, and Providence St. Joseph in Orange, California.

“The Laguna thrombectomy system is a valuable addition to the existing therapeutic options for venous thromboembolism,” commented John Moriarty, MD, in the company’s announcement. “The system offers excellent navigability and ease of use, enabling operators at all skill levels to remove clots efficiently. It addresses the need for large-volume clot removal in a range of vessel sizes in various anatomic locations within the peripheral vasculature." Dr. Moriarty is Professor of Interventional Radiology and Cardiology and Vice Chair of Clinical Research at UCLA David Geffen School of Medicine, in Los Angeles, California.

Additionally, Raj Khalsa, MD, said in the press release, “The design, with simplicity in mind, is a significant advantage in high-risk procedures. With increasing awareness of venous thromboembolism, the Innova system joins the ranks of a select few large-bore thrombectomy systems, with a remarkably efficient solution that offers substantial value to the health care system.”

The Laguna thrombectomy system, which received FDA 510(k) clearance last year, is composed of two devices developed by Innova Vascular: the Malibu aspiration catheter system and the Laguna clot retriever system.

According to the company, the Malibu aspiration catheter uses a gradient structural design and a hydrophilic coating for navigability through tortuous vessels. It is available in 12-, 16-, 20-, and 24-F outer diameters to address a variety of clot morphologies and vessel sizes.

Innova Vascular noted that Malibu can be used alone or in conjunction with the Laguna clot retriever, which has a self-expanding laser-cut nitinol design and is available in two diameters.